title: Effect of cytoskeleton disruptors on L-type Ca channel distribution in rat ventricular myocytes.
abstract: The cytoskeleton plays an important role in many aspects of cardiac cell function, including protein trafficking. However, the role of the cytoskeleton in determining Ca channel location in cardiac myocytes is unknown. In the present study we therefore investigated the effect of the cytoskeletal disruptors cytochalasin D, latrunculin, nocadazole and colchicine on the distribution of Ca channels in rat ventricular myocytes during culture for up to 96 h. During culture in the absence of these agents, cell edges became rounded, t-tubule density decreased, and the normal transverse distribution of the alpha1 (pore-forming) subunit of the L-type Ca channel became more punctate and peri-nuclear; these changes were associated with loss of synchronous Ca release in response to electrical stimulation. Disruption of tubulin using nocadazole or colchicine or sequestration of monomeric actin by latrunculin had no effect on these changes. In contrast, cytochalasin D inhibited these changes: cell shape, t-tubule density, transverse Ca channel staining and synchronous Ca release were maintained during culture. The protein synthesis inhibitor cycloheximide had similar effects to cytochalasin. These data suggest that cytochalasin stabilizes actin in adult ventricular myocytes in culture, thus stabilizing cell structure and function, and that actin is important in trafficking L-type Ca channels from the peri-nuclear region to the t-tubules, where they are normally located and provide the trigger for Ca release.
authors.affiliation: School of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, UK.
authors.forename: R N
authors.initials: RN
authors.lastname: Leach
authors.forename: J C
authors.initials: JC
authors.lastname: Desai
authors.forename: C H
authors.initials: CH
authors.lastname: Orchard
mesh_terms: D000199:Actins / Q000187:drug effects; D000818:Animals; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000187:drug effects / Q000378:metabolism*; D002478:Cells, Cultured; D003078:Colchicine / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D015638:Cytochalasin D / Q000494:pharmacology; D003598:Cytoskeletal Proteins / Q000037:antagonists & inhibitors*; D006352:Heart Ventricles / Q000166:cytology; D007150:Immunohistochemistry; D008297:Male; D008870:Microtubules / Q000187:drug effects; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D051381:Rats; D017208:Rats, Wistar; D013844:Thiazoles / Q000494:pharmacology; D053778:Thiazolidines; D014404:Tubulin / Q000187:drug effects
chemical_list: D000199:Actins; D019086:Bridged Bicyclo Compounds, Heterocyclic; D020746:Calcium Channels, L-Type; D003598:Cytoskeletal Proteins; D013844:Thiazoles; D053778:Thiazolidines; D014404:Tubulin; D015638:Cytochalasin D; D003513:Cycloheximide; D003078:Colchicine; C037067:latrunculin A